Japan's Sumitomo Dainippon Mulls $3B Roivant Drug Buy
Japanese pharmaceutical company Sumitomo Dainippon is considering buying Roivant's ownership interests in several biopharmaceutical companies for $3 billion upfront, the companies said early Friday....To view the full article, register now.
Already a subscriber? Click here to view full article